Literature DB >> 32345407

Evidence-based prescribing for post-traumatic stress disorder.

Jonathan I Bisson1, Amy Baker2, William Dekker2, Mathew D Hoskins3.   

Abstract

There is strong research evidence to support the pharmacological treatment of post-traumatic stress disorder (PTSD) as a second line to trauma-focused psychological interventions. Fluoxetine, paroxetine, sertraline and venlafaxine are the best-evidenced drugs, with lower-level evidence for other medications. It is important that prescribing for PTSD is evidence-based.

Entities:  

Keywords:  PTSD; evidence-based; pharmacotherapy; prescribing algorithm; treatment

Mesh：

Substances：

Year:  2020        PMID： 32345407     DOI： 10.1192/bjp.2020.40

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  4 in total

1.  Interventions to Improve the Mental Health of Mothers of Children with a Disability: Systematic Review, Meta-analysis and Description of Interventions.

Authors:  Helen M Bourke-Taylor; Den-Ching Angel Lee; Loredana Tirlea; Kahli Joyce; Prue Morgan; Terrence P Haines
Journal:  J Autism Dev Disord       Date:  2021-01-03

2.  A network pharmacology study with molecular docking to investigate the possibility of licorice against posttraumatic stress disorder.

Authors:  Zhi-Kun Qiu; Zhi-Ting Liu; Jia-Li Pang; Han-Biao Wu; Xu Liu; Ze-Min Yang; Xiong Li; Ji-Sheng Chen
Journal:  Metab Brain Dis       Date:  2021-08-21       Impact factor: 3.584

Review 3.  Managing COVID-19 related distress in primary care: principles of assessment and management.

Authors:  Laurence Astill Wright; Sam Gnanapragasam; Anthony J Downes; Jonathan I Bisson
Journal:  BMC Fam Pract       Date:  2021-04-14       Impact factor: 2.497

4.  Case report: Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder.

Authors:  Ping Guo; Yu Fang; Ming Feng; Xudong Zhao; Shikai Wang; Mincai Qian; Juanjuan Huang; Huanxin Chen
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.